Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer

Zin W. Myint; Jill M. Kolesar; Joseph Robert McCorkle; Jianrong Wu; Carleton S. Ellis; Danielle E. Otto; Peng Wang

doi:10.12659/MSM.938091

Back

Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer

Journal article

Open access

Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer

Zin W. Myint, Jill M. Kolesar, Joseph Robert McCorkle, Jianrong Wu, Carleton S. Ellis, Danielle E. Otto and Peng Wang

Medical science monitor, Vol.28, 938091

10/14/2022

DOI: 10.12659/MSM.938091

PMCID: PMC9578325

PMID: 36229939

Files and links (1)

url

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578325View

Published (Version of record) Open Access

Abstract

Background: Prostate cancer growth is primarily driven by testosterone and 5a-dihydrotestosterone. Abiraterone is an irre-versible inhibitor of CYP17, and CYP17 inhibition is a required step in testosterone biosynthesis. Previous stud-ies have shown that abiraterone trough levels are predictive of prostate-specific antigen (PSA) response in met-astatic castrate-resistant prostate cancer (mCRPC). It has not been demonstrated if this association exists for patients with metastatic hormone-sensitive prostate cancer (mHSPC). In this study, we aimed to explore the correlation and association between abiraterone trough levels and PSA levels in patients with mHSPC. Material/Methods: This was a single-center, prospective, observational study of patients with mHSPC being treated with abi-raterone acetate (AA) 1000 mg once daily. Abiraterone trough levels (22-26 h after drug administration) were drawn at 1, 3, and 7 months after treatment initiation. Results: Thirteen patients with mHSPC were enrolled, and complete pharmacokinetic data were available for 8 patients. The mean trough levels at 1 month, 3 months, and 7 months were 34.49 ng/mL (3.36-240.46), 13.82 ng/mL (2.91-29.96), and 15.7 ng/mL (3.58-26.86), respectively. The correlation between the 1-month abiraterone trough level and 1-month PSA level was 0.29 (P=0.38), between 3-month abiraterone trough and 3-month PSA was-0.61 (P=0.08), and between 7-month abiraterone trough and 7-month PSA was-0.31 (P=0.54). Conclusions: This study demonstrated a trend toward a negative correlation between 3-month abiraterone trough levels and PSA levels, but the correlation was not statistically significant. A study with a larger prospective sample size is needed to validate these findings.

Life Sciences & Biomedicine

Medicine, Research & Experimental

Research & Experimental Medicine

Science & Technology

Details

Title: Subtitle: Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer
Creators: Zin W. Myint - University of Kentucky
Jill M. Kolesar - University of Kentucky
Joseph Robert McCorkle - University of Kentucky
Jianrong Wu - New Mexico Cancer Center
Carleton S. Ellis - University of Kentucky
Danielle E. Otto - Markey Cancer Center
Peng Wang - University of Kentucky
Resource Type: Journal article
Publication Details: Medical science monitor, Vol.28, 938091
DOI: 10.12659/MSM.938091
PMID: 36229939
PMCID: PMC9578325
NLM abbreviation: Med Sci Monit
ISSN: 1234-1010
eISSN: 1643-3750
Publisher: Int Scientific Information, Inc
Number of pages: 8
Language: English
Date published: 10/14/2022
Academic Unit: Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
Record Identifier: 9984696553102771

Metrics

2 Record Views

1 Times Cited - Web of Science